Abstract We recruited 56 colorectal cancer patients and compared the mutational spectrum of tumor tissue DNA, circulating cell‐free DNA, and circulating tumor cell DNA to evaluate the potential of liquid biopsy to detect heterogeneity of cancer. Tumor tissue DNA, circulating cell‐free DNA, and circulating tumor cell DNA were extracted from each patient and were analyzed using next generation sequencing and digital PCR. To maximize yields of circulating tumor cells, three antibodies were used in...
Thu Aug 29, 2019 22:58
Abstract Ferroptosis is an iron‐dependent lipid peroxide cell death caused by inhibiting the cystine/glutamate transporter, which is of importance for the survival of triple‐negative breast cancer (TNBC) cells. Erastin is a low molecular weight chemotherapy drug that induces ferroptosis; however, poor water solubility and renal toxicity limited its application. Exosome, as drug delivery vehicles with low immunogenicity, high biocompatibility and high efficiency, have attracted attention in recent...
Thu Aug 29, 2019 11:44
État des lieux de la radiothérapie adaptative en 2019 : de la mise en place à l’utilisation clinique
Publication date: Available online 28 August 2019Source: Cancer/RadiothérapieAuthor(s): A. Badey, A. Barateau, N. Delaby, P. Fau, R. Garcia, R. De Crevoisier, A. LisbonaRésuméLa radiothérapie avec modulation d’intensité associée à un guidage par l’image en salle de traitement conduit à une irradiation de plus en plus précise. Cependant, de nombreux patients présentent des variations anatomiques en cours de traitement (intra ou interfraction) pouvant entraîner un « sous-dosage » tumoral et/ou un surdosage...
Thu Aug 29, 2019 17:03
Publication date: Available online 28 August 2019Source: Cancer/RadiothérapieAuthor(s): C. Hennequin, S. Guillerm, L. QueroAbstractChemoradiotherapy is now considered the standard of care for many locally advanced diseases. Cytotoxic drugs have been largely evaluated in this setting, with cisplatin and 5FU the most often used drugs. A large amount of pre-clinical studies has demonstrated the synergy between both modalities. Concomitant administration seems the more beneficial in many diseases. Emergence...
Thu Aug 29, 2019 17:03
Cancers, Vol. 11, Pages 1272: Cancer Takes a Toll on Skeletal Muscle by Releasing Heat Shock Proteins—An Emerging Mechanism of Cancer-Induced Cachexia Cancers doi: 10.3390/cancers11091272 Authors: Thomas K Sin Guohua Zhang Zicheng Zhang Song Gao Min Li Yi-Ping Li Cancer-associated cachexia (cancer cachexia) is a major contributor to the modality and mortality of a wide variety of solid tumors. It is estimated that cachexia inflicts approximately ~60% of all cancer patients...
03:00
Cancers, Vol. 11, Pages 1271: In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients Cancers doi: 10.3390/cancers11091271 Authors: Heeke Benzaquen Long-Mira Audelan Lespinet Bordone Lalvée Zahaf Poudenx Humbert Montaudié Dugourd Chassang Passeron Delingette Marquette Hofman Stenzinger Ilié Hofman Tumor mutational burden...
Thu Aug 29, 2019 03:00
Cancers, Vol. 11, Pages 1270: Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview Cancers doi: 10.3390/cancers11091270 Authors: Antonella Argentiero Antonio Giovanni Solimando Oronzo Brunetti Angela Calabrese Francesco Pantano Michele Iuliani Daniele Santini Nicola Silvestris Angelo Vacca Skeletal metastases of unknown primary (SMUP) represent a clinical challenge in dealing with patients diagnosed with bone metastases. Management...
Thu Aug 29, 2019 03:00
Cancers, Vol. 11, Pages 1269: Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection? Cancers doi: 10.3390/cancers11091269 Authors: Adrien Costantini Paul Takam Kamga Coraline Dumenil Thierry Chinet Jean-François Emile Etienne Giroux Leprieur Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience...
Thu Aug 29, 2019 03:00
Opinion statement Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000 new cases diagnosed annually in the USA. Although NETs are a diverse group of neoplasms, they share common molecular targets that can be exploited using nuclear medicine techniques for both imaging and therapy. NETs have traditionally been imaged with SPECT imaging using 111In-labeled octreotide analogs to detect neoplasms with somatostatin receptors. In addition, certain NETs (pheochromocytomas,...
Thu Aug 29, 2019 03:00
The original version of this article, which published in Current Treatment Options in Oncology, Volume 19, Issue 11, November 2018, contained an error within the Conflict of Interest statements. It was originally stated that “Norma E. Farrow received support from an NIH T32 grant (T32-CA009111.”
Thu Aug 29, 2019 03:00
Opinion statement Neuroendocrine neoplasia (NEN) represents a heterogenous group of tumours. Guidelines regarding treatment choice and sequencing remain complex given varied primary sites, hormone-secretory status, tumour grade, disease heterogeneity, and paucity of rigorous comparative trials due to rarity of this condition. However, there is increasing evidence that peptide receptor radionuclide therapy (PRRT) is an effective treatment, especially for grade 1 and 2 NEN. Primary...
Thu Aug 29, 2019 03:00
Future Oncology, Ahead of Print.
Thu Aug 29, 2019 06:21
Related ArticlesOptimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Future Oncol. 2019 Aug 28;: Authors: Pu N, Yin L, Habib JR, Gao S, Hu H, Zhu Y, Wu Y, Yu J, Lou W Abstract Aim: To reassess the prognostic performance of the American Joint Committee on Cancer (AJCC) 8th edition for Pancreatic ductal adenocarcinoma (PDAC) and optimize the categorization of PDAC staging. Patients &...
Thu Aug 29, 2019 16:37
For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in Feb‐2019 across Europe, will recruit 100 AYA patients (aged 12–29 years) with newly diagnosed or relapsed high‐grade gliomas...
Thu Aug 29, 2019 19:00
Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant side effect of chemotherapeutics. The mechanisms of CIPN remain substantially unidentified, although inflammation‐induced peripheral sensitization has been indicated as an important factor. Here, we aimed to illustrate the role of the matrix metalloproteinase (MMP)‐9‐related signaling pathway in the process of CIPN. Oxaliplatin was administered to mice to establish the CIPN model. Gelatin zymography was used to measure MMP‐9/2 activities....
Thu Aug 29, 2019 18:59
Renal cell carcinoma (RCC) is frequently diagnosed incidentally as an early‐stage small renal mass (SRM; pT1a, ≤ 4 cm). Overtreatment of patients with benign or clinically indolent SRMs is increasingly common and has resulted in a recent shift in treatment recommendations. There are currently no available biomarkers that can accurately predict clinical behaviour. Therefore, we set out to identify early biomarkers of RCC progression. We employed a quantitative label‐free LC‐MS/MS proteomics approach...
Thu Aug 29, 2019 17:59
Gastric cancer (GC) is the third leading cause of cancer deaths and the fourth most prevalent malignancy worldwide. The high incidence and mortality rates of gastric cancer result from multiple factors such as ineffective screening, diagnosis and limited treatment options. In this study, we sought to systematically identify predictive molecular networks and key regulators to elucidate complex interacting signaling pathways in GC. We performed an integrative network analysis of the transcriptomic...
Wed Aug 28, 2019 21:13
High rates of recurrence and metastasis are the major cause of the poor outcomes for patients with lung cancer. In previous research, we have demonstrated that Tac2-N promotes tumor growth by suppressing p53 s...
03:00
Anti-angiogenesis remains an attractive strategy for cancer therapy. Some anti-angiogenic reagents have bell-shape dose-response curves with higher than the effective doses yielding lower anti-angiogenic effec...
Wed Aug 28, 2019 03:00
Accumulating evidence demonstrates the oncogenic roles of lncRNA (long non-coding RNA) molecules in a wide variety of cancer types including glioma. Equally important, However, tumorigenic functions of lncRNA ...
Wed Aug 28, 2019 03:00
Gene rearrangement is reported to be associated to the aggressive phenotype and poor prognosis in prostate cancer (CaP). We identified a gene-fusion between a transcription repressor (BMI1) and transcriptional factor (COMMD3) in human CaP. We show that COMMD3:BMI1 fusion expression is significantly increased in CaP disease in an order: normal tissue < primary < metastatic-tumors (Mets). Although elevated TMPRSS-ERG/ETV fusion is reported in CaP, we identified a subtype of Mets exhibiting low...
Thu Aug 29, 2019 16:52
Cancer precision medicine aims to predict the drug likely to yield the best response for a patient. Genomic sequencing of tumours is currently being used to better inform treatment options, however, this approach has had a limited clinical impact due to the paucity of actionable mutations. An alternative to mutation status is the use of gene expression signatures to predict response. Using data from two large-scale studies, The Genomics of Drug Sensitivity of Cancer (GDSC) and The Cancer Therapeutics...
Thu Aug 29, 2019 16:52
Melanoma patients have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood-brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. DCE-MRI was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated...
Thu Aug 29, 2019 16:52
DNA repair mechanisms are crucial for cell survival. It increases the cancer cell's ability to resist DNA damage. FEN1 involves in DNA replication and repair, specifically long patch base excision repair. Although the gene function and post-translational modification of FEN1 are well studied, the regulatory mechanism of FEN1 by upstream signal pathways remains unclear. In this paper, we have identified AKT as a regulator of FEN1 activity in lung cancer cells. Sustained activation of AKT can phosphorylate...
Thu Aug 29, 2019 16:52
Abstract Chemoresistance is the primary cause of chemotherapy failure. Compelling evidence shows that micro RNAs (miRNAs) contribute to reprogram cancer cells toward a resistant phenotype. We investigate the role of miRNAs in the response to acute treatment with 5‐FU in colon cancer‐resistant cells. We performed a global gene expression profile for the entire miRNA genome and found a change in the expression of four miRNAs following acute treatment with 5‐FU. Among them, we focused on miR‐210‐3p,...
Thu Aug 29, 2019 19:59
Abstract Sorafenib is the standard first‐line systemic chemotherapeutic drugs for advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is frequently observed in clinical practice. In this study, we first produced three sorafenib resistance (SR) HCC cell lines by using two human HCC cell lines (Hep3B and Huh7) and a human primary HCC cell line. We identified that epidermal growth factor receptor (EGFR) and Kruppel‐like factor 4 (KLF4) are dramatically increased in the three...
Thu Aug 29, 2019 15:56
Publication date: September–October 2019Source: Practical Radiation Oncology, Volume 9, Issue 5Author(s): Manisha Palta, Devon Godfrey, Karyn A. Goodman, Sarah Hoffe, Laura A. Dawson, David Dessert, William A. Hall, Joseph M. Herman, Alok A. Khorana, Nipun Merchant, Arti Parekh, Caroline Patton, Joseph M. Pepek, Joseph K. Salama, Richard Tuli, Albert C. KoongAbstractPurposeThis guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant,...
Thu Aug 29, 2019 14:15
Publication date: September–October 2019Source: Practical Radiation Oncology, Volume 9, Issue 5Author(s):
Thu Aug 29, 2019 14:15
Publication date: September–October 2019Source: Practical Radiation Oncology, Volume 9, Issue 5Author(s):
Thu Aug 29, 2019 14:15
Publication date: September–October 2019Source: Practical Radiation Oncology, Volume 9, Issue 5Author(s):
Thu Aug 29, 2019 14:15
Abstract Objective Mindfulness‐based interventions (MBIs) are increasingly used within psycho‐oncology. Since the publication of the most recent comprehensive meta‐analysis on MBIs in cancer in 2012, the number of published trials has more than doubled. We therefore conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs), testing the efficacy of MBIs on measures of psychological distress (primary outcome) and other health outcomes in cancer patients and ‐survivors....
Thu Aug 29, 2019 11:47
The nadA motif is a riboswitch candidate present in various Acidobacteria species that was previously identified by bioinformatic analysis of bacterial DNA datasets. Over 100 unique representatives have been identified exclusively upstream of nadA genes, which code for an enzyme in the biosynthetic pathway of the ubiquitous coenzyme NAD+. The architecture of nadA motif RNAs suggests they employ structurally similar tandem ligand-binding aptamer domains to control translation initiation. Biochemical...
Thu Aug 29, 2019 20:05
The RNA world hypothesis relies on the ability of ribonucleic acids to replicate and spontaneously acquire complex structures capable of supporting essential biological functions. Multiple sophisticated evolutionary models have been proposed for their emergence, but they often assume specific conditions. In this work we explore a simple and parsimonious scenario describing the emergence of complex molecular structures at the early stages of life. We show that at specific GC-content regimes, an undirected...
Thu Aug 29, 2019 18:06
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Sophia K. McKinley, Akhil Chawla, Cristina R. Ferrone
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Amy C. Taylor, Dilip Maddirela, Sarah B. White
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Saeed Sadeghi, Anthony Bejjani, Richard S. Finn
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Susan Tsai, T. Clark Gamblin
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Geoffrey W. Krampitz, Thomas A. Aloia
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Rachel M. Lee, Shishir K. Maithel
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Leonid Cherkassky, Michael D’Angelica
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Ramy El-Diwany, Timothy M. Pawlik, Aslam Ejaz
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Benjamin L. Green, Michael G. House
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Janelle F. Rekman, Philip Smith, Morgan Bonds, David Coy, Scott Helton
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): Alan W. Hemming
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s):
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s):
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s):
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s):
Thu Aug 29, 2019 20:33
Publication date: October 2019Source: Surgical Oncology Clinics of North America, Volume 28, Issue 4Author(s): T. Clark Gamblin
Thu Aug 29, 2019 20:33
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου